Yaygın anksiyete bozukluğu tedavisinde karşılanmamış gereksinimler: Yeni bir seçenek pregabalin

Yaygın anksiyete bozukluğu (YAB) yaşam boyu yaygınlığı %5 oranında, engelleyici belirtileri olan kronik bir psikiyatrik bozukluktur. Medikal ve psikiyatrik diğer hastalıklarla da yüksek komorbidite gösteren bu bozukluk yaşam kalitesini bozarak kişisel ve ekonomik yük oluşturmaktadır. Uzun süreli YAB tedavisinde amaç ruhsal ve bedensel belirtileri azaltmak, uykuyu düzenlemek, hastanın işlevlerini iyileştirmek, yaşam kalitesini artırmak, komorbid durumları tedavi etmek ve sonuç olarak remisyon sağlamak ve relapsları önlemektir. Mevcut tedavi seçeneklerinin dezavantajlarını taşımayan ve anksiyeteyi etkili bir şekilde tedavi edebilen yeni ajanlara gereksinme duyulması, nöroanatomi ve nörokimya alanlarındaki gelişmeler sonucu son yıllarda yeni düzenekler üzerinden etkili ve güvenilir tedavi seçenekleri kullanıma sunulmuştur. Bu yazıda YAB için ilaç tedavisi gözden geçirilmiş ve kullanıma yeni giren ilaçlar arasında ümit vaat eden pregabaline ayrıca değinilmiştir. (Anadolu Psikiyatri Derg 2012; 13:232-238)

Unmet needs in the generalized anxiety disorder: pregabalin as a new option

Generalized anxiety disorder (GAD) is a chronic psychiatric disorder with a lifetime prevalence of 5% and with dis- abling symptoms. The disorder, which shows high comorbidity with other medical and psychiatric diseases, poses personal and economic burden by deteriorating the quality of life. The aim of the long-term GAD treatment is to reduce psychic and somatic symptoms, to regulate the sleep, improve the functions of the patient, improve the quality of life, to treat the comorbid conditions, and finally to provide remission and prevent relapses. Recently, effective and safe treatment options that act through new mechanisms were brought into use due to the requirement for new agents that can effectively treat anxiety without causing problems associated with current treatment approaches, and due to advances in the fields of neuroanatomy and neurochemistry. In this study, pharmacotherapy for GAD was reviewed and pregabalin, which seems promising among the other drugs that have been newly introduced, was also mentioned. (Anatolian Journal of Psychiatry 2012; 13:232-238)

___

  • Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Pre- valence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617-627.
  • Wittchen HU, Kessler RC, Beesdo K, Krause P, Höfler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63(Suppl.8): 24-34.
  • Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry 2000; 176:544-549.
  • Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16:162-171.
  • Mogotsi M, Kaminer D, Stein DJ. Quality of life in the anxiety disorders. Harv Rev Psychiatry 2000; 8:273-282.
  • DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety 1996; 2:167-172.
  • Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999; 60:427-435.
  • Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry 1996; 168:308-313.
  • Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry 2009; 70(Suppl.2):32-38.
  • Dilbaz N. Yaygın anksiyete bozukluğu olan hastalarda yanlış teşhis ve tedavi nedeniyle meydana gelen hasta yükünün değerlendirilmesi çalışması. Ön sonuçları (yayında).
  • Dilbaz N, Yalcın Cavus S, Enez Darcin A. Treatment resistant generalized anxiety disorder. S Selek (Ed.), Different Wiews of Anxiety Disorders, InTech Open Access Book, 2011, p.219-232.
  • Davidson JR, Feltner DE, Dugar A. Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs. Prim Care Companion J Clin Psychiatry 2010; 12. pii:
  • Allgulander C. Novel approaches to treatment of generalized anxiety disorder. Curr Opin Psychiatry 2010; 23:37-42.
  • Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19:567- 596.
  • Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, Zohar J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessivecompulsive and posttraumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9:248-312.
  • Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006; 51(Suppl.2):51S-56S.
  • Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007; 7:769-781.
  • Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ 2011; 342:d1199.
  • Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71:839- 854.
  • Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2001; 62(Suppl.11):46-50; discussion 51-52.
  • Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67:41-47.
  • Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol 2006; 16(Suppl. 2):S128-S133.
  • Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9:495-505.
  • Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002; 36:209-217.
  • Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59:211-215.
  • Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66:1321-1325.
  • Pandina GJ, Canuso CM, Turkoz I, Kujawa M, Mahmoud RA. Ad- junctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull 2007; 40:41-57.
  • Hoge EA, Worthington JJ 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr 2008; 13:522-527.
  • Menza MA, Dobkin RD, Marin H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007; 27:207-210.
  • Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005; 25:497-499.
  • Simon NM. Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse. J Clin Psychiatry 2009; 70(Suppl.2):10-14.
  • Culpepper L. Generalized anxiety disorder and medical illness. J Clin Psychiatry 2009; 70(Suppl.2):20-24.
  • Davidson JR. First-line pharmacotherapy approaches for generalized anxiety disorder. J Clin Psychiatry 2009; 70(Suppl.2):25-31.
  • Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010; 50:941-950.
  • Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 2006; 6:108-113.
  • Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007; 29:26-48.
  • Gale CK, Millichamp J. Generalised anxiety disorder. Clin Evid (Online) 2007; 2007. pii: 1002.
  • Greist JH, Liu-Dumaw M, Schweizer E, Feltner D. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26- week study. Int Clin Psychopharmacol 2011; 26:243-251.
  • Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled week trial. Int Clin Psychopharmacol 2009; 24:87-96.
  • Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13:229-241.
  • LaLonde CD, Van Lieshout RJ. Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J Clin Psychopharmacol 2011; 31:326-333.
  • Rickels K, Shiovitz TM, Ramey TS, Weaver JJ, Knapp LE, Miceli JJ. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. Int Clin Psychopharmacol 2012; 27:142-150.
  • Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol 2012; 26:461-470.
  • Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007; 3:185-191.
  • Baldwin DS, Schweizer E, Xu Y, Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? Eur Neuropsychopharmacol 2012; 22:137-142.
  • Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160:533-540.
  • Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlledfixed-dose, multicenter study of pregabalin in patients with gener- alized anxiety disorder. J Clin Psychopharmacol 2003; 23:240-249.
  • Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62:1022-1030.
  • Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25:151-158.
  • Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a doubleblind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26:213-220. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 2012; 46:424-429.
  • Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebocontrolled trials. Pharmacopsychiatry 2007; 40:163-168.
  • Montgomery S, Chatamra K, Pauer L, Whalen E, Baldinetti F. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry 2008; 193:389-394.
  • Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23:18-28.
  • Montgomery SA, Herman BK, Schweizer E, Mandel FS. The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. Int Clin Psychopharmacol 2009; 24:214-222.
  • Stein DJ, Bruce Lydiard R, Herman BK, Mandel FS. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009; 24:126-132.
  • Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18:422-430.
  • Samuel M, Zimovetz EA, Gabriel Z, Beard SM. Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol 2011; 26:63-68.
  • Strawn JR, Geracioti TD Jr. The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic. Neuropsychiatr Dis Treat 2007; 3:237-243.
  • Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ 2010; 11:35-44.
Anadolu Psikiyatri Dergisi-Cover
  • ISSN: 1302-6631
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 2000
  • Yayıncı: -
Sayıdaki Diğer Makaleler

Yatarak tedavi gören psikiyatri hastalarında işlevselliğin genel değerlendirilmesi ve ilişkili etkenler: Geriye dönük bir çalışma

İSMET KIRPINAR, MELTEM ORAL

Sosyal Destek Davranışları Ölçeğinin uyarlama, güvenilirlik ve geçerlilik çalışması

Ruth Yasemin EROL, ÖZLEM BOZO ÖZEN

Genderdifference in performance and perception abouttools in fifth year psychiatry attachment assessment

Mostafa AMR

Psiko-onkoloji ve aile hekimliğinde ruh sağlığını güçlendirme: Sosyal destek algısı ve psikodrama grup terapisi uygulamaları

Derya AKBIYIK İREN, Haldun SOYGÜR, Erdem KARABULUT

Zonguldak il merkezinde kadın cinsel sorunlarının yaygınlığı ve cinsel sorunlarla ilgili etkenler

Ülkem ÖZTÜRK ANGIN, NURAY ATASOY, ÖZGE SARAÇLI, MEHMET ALİ KURÇER, Elif KARAAHMET

The etiology of anxiety disorders

Orhan DOĞAN

Yaygın anksiyete bozukluğu tedavisinde karşılanmamış gereksinimler: Yeni bir seçenek pregabalin

Nesrin DİLBAZ, Kayıhan Oğuz KARAMUSTAFALIOĞLU

İlk akut miyokart infarktüsü sonrası erken dönemde depresyon

ERDEM DEVECİ, EROL OZAN, Mustafa GÜLEÇ, İSMET KIRPINAR

Tekrarlayıcı Düşünme Ölçeği ve Bilişsel Esneklik Envanterinin Türkçeye uyarlanması, geçerliliği ve güvenilirliği

İ. Volkan GÜLÜM, İHSAN DAĞ

Treatment options of delusional parasitosis: case series of 14 patientsprivate

BEHÇET COŞAR, Kardem TAŞKINOĞLU, Peter LEEPING, Sabri BURHANOĞLU, HALE YAPICI ESER, Mustafa Ender TANER, Zehra ARIKAN